Research & Formulation

From Lab Sample to Launch: Build a Clear Development Handover

A well-liked sample is a milestone, not a complete launch file. The handover should show the next team exactly what has been approved, what evidence exists and which decisions remain open.

Anadoris editorial concept artwork; not a photograph of a facility or customer installation.
Anadoris editorial concept artwork; not a photograph of a facility or customer installation.

From Anadoris. This guide comes from the team behind Manufacturing & Development: formulation, packaging and production for other brands, from brief to finished batch. About the group.

Identify the approved combination

Record the formula version, packaging components, pack size and artwork version together. Link them to the relevant approval records. This prevents a launch team from combining an approved formula with an earlier label or a substitute component that has not been assessed through the appropriate process.

Include the approved sensory reference and the agreed specifications under the technical team’s control. Explain where reference samples and records are kept and who can clarify them. Avoid relying on one person’s memory of which bottle looked right at the final meeting.

Connect claims with their evidence

Provide the approved claims list and the evidence references behind it. Clearly distinguish completed assessments from planned work. If a claim or destination-specific question is unresolved, keep it visible as an open action rather than allowing the marketing deadline to turn it into an assumption.

The FDA explains that safety assessment can involve available ingredient information and additional work relevant to the finished product in the US context. The applicable process for any launch should be defined by qualified technical and regulatory teams for its markets. A sensory approval alone cannot answer all safety or compliance questions.

Assign the remaining decisions

List open actions with an owner, the evidence required to close them and the consequence for the launch plan. Separate production readiness, artwork readiness and commercial timing so that progress in one area does not hide a blocker in another. Review changes through the agreed approval route.

Hold a short handover meeting in which the receiving team explains the file back to the development owner. Ask which version they will use, what is approved and what remains outstanding. Any hesitation reveals a gap worth closing before work proceeds. A clear handover preserves the reasoning that created the product.

Sources

  • {'title': 'FDA: Product testing of cosmetics (US context)', 'url': 'https://www.fda.gov/cosmetics/cosmetics-science-research/product-testing-cosmetics'}

Questions

What is the essential handover document?

A version-linked record connecting the approved product configuration, supporting evidence, approvals and open actions. Its format can be simple if the connections are clear.

Who decides whether the product can be released?

The authorised owners under the organisation’s technical, quality, regulatory and commercial processes. This editorial checklist does not replace those responsibilities.

Your next chapter

Talk to the team behind this.

Manufacturing & Development: Formulation, packaging and production for other brands, from brief to finished batch.

Discuss manufacturing